Skip to main content
OpenTrials

Clinical trial condition

Blood Protein Disorders

Explore clinical trials studying Blood Protein Disorders. Study availability and eligibility vary by location and protocol.

3,039 public trials 566 recruiting studies
Refine in advanced search Browse all conditions

Blood Protein Disorders trial results

Completed

Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma

NCT00003007

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • William F. Bowld Hospital Memphis, Tennessee, United States
  • Methodist Healthcare - Hospital of Memphis Memphis, Tennessee, United States
  • Baptist Memorial Hospital Memphis, Tennessee, United States
  • University of Tennessee, Memphis Memphis, Tennessee, United States
View Trial Details
Completed

Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00022607

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • USC/Norris Comprehensive Cancer Center and Hospital Los Angeles, California, United States
  • University of California Davis Cancer Center Sacramento, California, United States
  • University of Chicago Cancer Research Center Chicago, Illinois, United States
View Trial Details
Completed

Interleukin-12 in Treating Patients With Multiple Myeloma

NCT00003149

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Indiana University Cancer Center Indianapolis, Indiana, United States
  • Veterans Affairs Medical Center - Indianapolis (Roudebush) Indianapolis, Indiana, United States
  • CCOP - Iowa Oncology Research Association Des Moines, Iowa, United States
  • CCOP - Ochsner New Orleans, Louisiana, United States
View Trial Details
Completed

Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency

NCT00520494

Conditions
Agammaglobulinemia, Blood Protein Disorders, Bruton type agammaglobulinemia, +10 more
Locations
  • Contact CSL Behring for facility details Edmonton, Alberta, Canada
  • Contact CSL Behring for facility details Montreal, Quebec, Canada
  • Contact CSL Behring for facility details Leipzig, Germany
  • Contact CSL Behring for facility details Brescia, Italy
View Trial Details

Related conditions